ArticleBreast cancer research : BCR2023

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.

Jeongmin Seo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.